Lin said that it costs about $2 billion to develop a drug in the private sector, while NIH-funded research produces a drug at ...

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected ...

The new EU label is broader than in the US, where the FDA approved Xofluza last August for treatment in children aged five years and older and post-exposure prophylaxis in those aged over 12.

pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s antiviral drug can play ... have developed a pan-coronavirus vaccine rather ...

Meowtel explored advancements in feline medicine, nutrition, and care that are helping the more than 350 million domestic ...

Pfizer Inc. announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...